May 16, 2022

Botu Linum

The Car & Automotive Devotees

MassBio announces line-up for its biotech accelerator

4 min read

The Massachusetts Biotechnology Council (MassBio) has just revealed the five emerging biotech companies chosen to participate in the spring 2022 cohort of its accelerator program.

The initiative, called MassBioDrive, looks to harness the power of the organization’s global life sciences network to help new founders launch their startups more effectively and efficiently.

“The science and technologies that these companies are pioneering represent the future of the life sciences. From simplifying CAR-T production to developing new therapeutics for acute kidney injury patients, the MassBioDrive spring cohort has enormous potential to address pressing unmet medical needs,”​ said Joe Boncore, CEO of MassBio.

What’s in it for the startups?

Over the course of the eight-week program, the selected startups will participate in growth-focused business training taught by seasoned experts, and they will partner with a small, dedicated group of industry mentors.

The companies will also receive a stipend award from Bristol Myers Squibb (BMS) and access to and/or resources from MassBioDrive partners.

The startups were selected following a rigorous vetting and interview process, led by a review board of industry leaders, said MassBio.

The line-up

Artificial Axon Labs, Topsfield, Massachusetts

Artificial Axon Labs is developing a drug discovery platform aimed at neurodegenerative diseases. Its technology, developed by the company founders at MIT, combines biocompatible materials, 3D printing of axon mimics, and patient-derived human cells to generate remyelinating drugs for multiple sclerosis.